PDS Biotechnology (NASDAQ:PDSB) Rating Reiterated by HC Wainwright

PDS Biotechnology (NASDAQ:PDSB)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued on Thursday, Benzinga reports. They presently have a $21.00 price target on the stock.

Separately, Alliance Global Partners upgraded shares of PDS Biotechnology to a “strong-buy” rating in a research note on Wednesday, August 21st. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, PDS Biotechnology has a consensus rating of “Moderate Buy” and an average target price of $14.25.

PDS Biotechnology Stock Performance

Shares of PDS Biotechnology stock opened at $3.12 on Thursday. The business’s fifty day simple moving average is $3.26 and its 200 day simple moving average is $3.27. The company has a current ratio of 3.84, a quick ratio of 3.84 and a debt-to-equity ratio of 0.45. PDS Biotechnology has a 12 month low of $2.53 and a 12 month high of $6.85. The firm has a market capitalization of $114.44 million, a P/E ratio of -2.29 and a beta of 1.90.

PDS Biotechnology (NASDAQ:PDSB) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.08. During the same quarter in the previous year, the company earned ($0.37) earnings per share. As a group, analysts anticipate that PDS Biotechnology will post -1.24 EPS for the current year.

Hedge Funds Weigh In On PDS Biotechnology

Several large investors have recently modified their holdings of the business. Kathleen S. Wright Associates Inc. purchased a new position in shares of PDS Biotechnology in the first quarter valued at $28,000. Tempus Wealth Planning LLC purchased a new position in PDS Biotechnology during the 2nd quarter valued at about $55,000. Ground Swell Capital LLC bought a new stake in shares of PDS Biotechnology during the second quarter valued at about $67,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of PDS Biotechnology in the second quarter worth about $115,000. Finally, Squarepoint Ops LLC bought a new position in shares of PDS Biotechnology in the second quarter valued at approximately $120,000. Hedge funds and other institutional investors own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.